Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial

Context Nearly 1 million hospitalizations for chronic heart failure occur yearly in the United States, with most related to worsening systemic congestion. Diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. Objective To evaluate the short- and intermediate-term effects of tolvaptan in patients hospitalized with heart failure. Design, Setting, and Participants Randomized, double-blind, placebocontrolled, parallel-group, dose-ranging, phase 2 trial conducted at 45 centers in the United States and Argentina and enrolling 319 patients with left ventricular ejection fraction of less than 40% and hospitalized for heart failure with persistent signs and symptoms of systemic congestion despite standard therapy.

[1]  R. A. Johnson,et al.  Heart failure in outpatients: a randomized trial of digoxin versus placebo. , 1982, The New England journal of medicine.

[2]  G. Fonarow,et al.  Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.

[3]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[4]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[5]  M. Gheorghiade,et al.  Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial , 2003, Circulation.

[6]  J. Ouyang,et al.  Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination , 2002 .

[7]  S. Goldstein,et al.  Relation of left ventricular chamber shape in patients with low (< or = 40%) ejection fraction to severity of functional mitral regurgitation. , 1995, The American journal of cardiology.

[8]  M. Drazner,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[9]  P. Lapuerta,et al.  A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. , 2001, Journal of cardiac failure.

[10]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[11]  Y. Yamamura,et al.  Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. , 2000, The Journal of pharmacology and experimental therapeutics.

[12]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[13]  A. Tuttolomondo,et al.  Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. , 2003, American heart journal.

[14]  S. Goldsmith.  Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. , 2002, Congestive heart failure.

[15]  T. Berl,et al.  Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. , 1981, The New England journal of medicine.

[16]  T Yamashita,et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[17]  V. Hasselblad,et al.  Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.

[18]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[19]  C. O'connor,et al.  Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. , 2003, American heart journal.

[20]  G. Fonarow,et al.  The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[21]  C. O'connor,et al.  Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. , 2003, The American journal of cardiology.

[22]  J. Croft,et al.  Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. , 1999, American heart journal.

[23]  W. Stevenson,et al.  Sudden Death Prevention in Patients With Advanced Ventricular Dysfunction , 1993, Circulation.

[24]  J. Ouyang,et al.  Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy , 2003 .

[25]  G. Francis,et al.  Arginine vasopressin and the renal response to water loading in congestive heart failure. , 1986, The American journal of cardiology.

[26]  M. Domanski,et al.  Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. , 1999, Circulation.

[27]  C. O'connor,et al.  Vasopressin: a new target for the treatment of heart failure. , 2003, American heart journal.

[28]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[29]  L. Rydén,et al.  Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. , 2003, Journal of the American College of Cardiology.

[30]  E. Espiner,et al.  Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. , 1980, Clinical science.